Public biotechnology 2002 - The numbers

Nature Biotechnology

Volumn 21, Issue 6, 2003, Pages 607-612

  Lähteenmäki, Riku ^a   DeFrancesco, Laura ^a  

^a NONE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALVIMOPAN; GASTROINTESTINAL AGENT; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CONSTIPATION; DRUG INDUSTRY; DRUG RESEARCH; ECONOMIC ASPECT; EMPLOYMENT; ENZYME REPLACEMENT; FABRY DISEASE; FINANCIAL MANAGEMENT; INCOME; PRIORITY JOURNAL; REVIEW; SMALLPOX; VACCINATION; VIRUS HEPATITIS; VIRUS INFECTION;

VARIOLA VIRUS;

EID: 0037686106     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0603-607     Document Type: Review

References (5)

1. Burrill, G.S. Biotech Endures: Looking Back at 2002 and Ahead to 2003. Genomic Proteomic Technology (January/February, 2003).
2. Bouchie, A. Biotechs slimming down. Nat. Biotechnol. 20, 864, 2002.
3. Crocker, G. Endurance: The European biotechnology report 2003. (Ernst & Young, New York, NY, 2003).
4. Lahteenmaki, R. & Fletcher, E. Public Biotechnology 2001 - the numbers. Nat. Biotechnol. 20, 551-555, 2002.
5. Hodgson, J. Future trends in biotechnology mergers and acquisitions. (Ernst & Young, New York, NY, 2002).